Matches in Nanopublications for { ?s ?p "[Deregulation of cyclin A2 by RARalpha-PLZF may represent an oncogenic mechanism of this chimeric protein and contribute to the aggressive clinical phenotype of t(11;17)(q23;q21)-associated APL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[Deregulation of cyclin A2 by RARalpha-PLZF may represent an oncogenic mechanism of this chimeric protein and contribute to the aggressive clinical phenotype of t(11;17)(q23;q21)-associated APL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Deregulation of cyclin A2 by RARalpha-PLZF may represent an oncogenic mechanism of this chimeric protein and contribute to the aggressive clinical phenotype of t(11;17)(q23;q21)-associated APL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP245797.RAVsuvq3rm4PqfqgON2uLu8ie3y3Mso2EnlASD9bvlI1U130_assertion description "[Deregulation of cyclin A2 by RARalpha-PLZF may represent an oncogenic mechanism of this chimeric protein and contribute to the aggressive clinical phenotype of t(11;17)(q23;q21)-associated APL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP245797.RAVsuvq3rm4PqfqgON2uLu8ie3y3Mso2EnlASD9bvlI1U130_provenance.
- NP287595.RAuQ02Oj2Rpa5trj6I0TSLzlLE0MRjnTXI7NoAuHOfYiE130_assertion description "[Deregulation of cyclin A2 by RARalpha-PLZF may represent an oncogenic mechanism of this chimeric protein and contribute to the aggressive clinical phenotype of t(11;17)(q23;q21)-associated APL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP287595.RAuQ02Oj2Rpa5trj6I0TSLzlLE0MRjnTXI7NoAuHOfYiE130_provenance.
- NP751837.RAGbq5ModjpVE3jKxNvqG38KIb0BgxO6yLlCujEpghUjQ130_assertion description "[Deregulation of cyclin A2 by RARalpha-PLZF may represent an oncogenic mechanism of this chimeric protein and contribute to the aggressive clinical phenotype of t(11;17)(q23;q21)-associated APL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP751837.RAGbq5ModjpVE3jKxNvqG38KIb0BgxO6yLlCujEpghUjQ130_provenance.
- NP245796.RAoV0sJa2lgRoEVawUXZsYSofFcvSKBL23kk2Ee_1_jk8130_assertion description "[Deregulation of cyclin A2 by RARalpha-PLZF may represent an oncogenic mechanism of this chimeric protein and contribute to the aggressive clinical phenotype of t(11;17)(q23;q21)-associated APL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP245796.RAoV0sJa2lgRoEVawUXZsYSofFcvSKBL23kk2Ee_1_jk8130_provenance.